Connected Continuous Glucose Monitoring Systems Industry Research Report QYResearch has recently released the industry report “2026 Connected Continuous Glucose Monitoring Systems Industry Research Report,” covering product definition, technology routes, market size, competitive landscape, application scenarios, regional structure and supply chain changes. This brief focuses on demand shifts, technology evolution and supply chain opportunities for connected CGM systems in diabetes management, insulin therapy support, remote health monitoring, in-hospital and out-of-hospital chronic disease management, and metabolic health management. Connected Continuous Glucose Monitoring Systems refer to medical and health monitoring systems that continuously or frequently monitor glucose levels in interstitial fluid and use sensors, transmitters, readers, smartphone applications or cloud platforms to enable data recording, trend analysis, alerts and remote sharing. Such systems usually consist of disposable or replaceable glucose sensors, low-power wireless modules, wearable attachment structures, algorithm software, mobile applications and data management platforms. Their core functions include real-time glucose trend display, hypoglycemia and hyperglycemia alerts, glucose variability analysis, time-in-range management, and data linkage with physicians, caregivers, family members or insulin delivery systems. This promotional brief focuses on CGM systems with connectivity, data sharing, mobile application or cloud management capability. The research object mainly covers real-time patch CGM, intermittently scanned CGM, long-term implantable CGM, CGM integrated with automated insulin delivery systems, and related software, data platforms and consumable services. Major applications include type 1 diabetes, insulin-treated type 2 diabetes, gestational diabetes management, hospital and post-discharge care, remote chronic disease management and metabolic health monitoring. According to QYResearch preliminary research, the global Connected Continuous Glucose Monitoring Systems market size was approximately US$14,450.00 million in 2025 and approximately US$16,700.00 million in 2026. It is expected to reach approximately US$32,611.24 million by 2032, with a CAGR of around 11.80% during 2026–2032. The above scale mainly covers patch, sensor-based and implantable connected CGM systems equipped with Bluetooth, mobile apps, cloud synchronization, data sharing or connectivity with insulin pumps and automated delivery systems, together with related consumables, readers and software service revenue. From the demand side, growth is mainly driven by the expanding global diabetes population, higher monitoring frequency among insulin-treated patients, improving insurance coverage, digitalization of out-of-hospital chronic disease management, wider home health monitoring adoption, and increasing clinical recognition of dynamic metrics such as time in range. According to the International Diabetes Federation’s 2025 data, about 589 million adults aged 20–79 were living with diabetes worldwide in 2024, and the number is projected to reach about 853 million by 2050, providing a solid demand background for long-term CGM penetration. On the supply side, leading companies are investing in miniaturized sensors, longer wear duration, factory calibration, low-power Bluetooth connectivity, algorithm platforms, AID compatibility, OTC consumer products and emerging market channels. Overall, the industry is moving from core diabetes treatment users toward broader chronic disease management and metabolic health scenarios, with future incremental demand mainly from type 2 diabetes users, public reimbursement inclusion, lower-cost localized products, commercialization of long-term implantable solutions, and deeper integration with insulin pumps, smart pens, telemedicine and AI-based data analytics platforms. The global Connected Continuous Glucose Monitoring Systems market is relatively concentrated. Abbott and Dexcom are the leading companies with the strongest scale advantages and brand influence worldwide. Abbott has built broad medical and consumer channel coverage through its FreeStyle Libre series, while Dexcom maintains leadership in real-time CGM, connectivity ecosystems and diabetes technology platforms through its G-series products. Dexcom reported 2025 worldwide revenue of approximately US$4.662 billion and launched the Dexcom G7 15 Day CGM system in 2025, showing that leading players continue to strengthen competitiveness through wear duration, connected ecosystems and payer coverage. Abbott reported that its continuous glucose monitor sales reached approximately US$2.0 billion in the fourth quarter of 2025 with strong growth, confirming CGM as a high-growth core category within medical devices. The second tier and specialized vendors include Medtronic, Senseonics, Ascensia Diabetes Care, ecosystem partners of Insulet and Tandem, Ypsomed-related ecosystem players, Medtrum, MicroTech Medical, SIBIONICS, Sinocare, Yuwell and POCTech. Medtronic is strengthening CGM and insulin pump integration around MiniMed 780G and Simplera Sync, while Senseonics differentiates itself through the long-term implantable Eversense 365 route. Chinese vendors are progressing rapidly in sensor fabrication, low-cost supply, online and offline channels, and domestic registration. Companies such as SIBIONICS, MicroTech Medical, Sinocare, Yuwell and POCTech are becoming important regional competitors. Future competition will shift from single-device accuracy toward system-level competition across sensor life, algorithm reliability, reimbursement capability, ecosystem connectivity, data services and regulatory compliance. By commonly used product form, connected CGM systems can be classified into short-cycle patch CGM, reusable-transmitter sensor CGM, long-term implantable CGM and integrated CGM used with automated insulin delivery systems. Short-cycle patch CGM is currently the fastest-growing and most widely adopted product type due to wearing convenience, smartphone connectivity and scalable manufacturing. Reusable transmitter solutions have cost and sustainability advantages in selected markets. Long-term implantable CGM focuses on longer wear duration and reduced sensor replacement frequency. Integrated CGM mainly serves type 1 diabetes and intensive insulin therapy users and is a key input for closed-loop glucose control and artificial pancreas systems. FDA’s product classification describes integrated CGM as a system intended to automatically measure glucose in bodily fluids continuously or frequently and used with digitally connected devices, reinforcing the industry focus on accuracy, interoperability and risk control. By application, diabetes treatment remains the core market. Type 1 diabetes, insulin-intensive type 2 diabetes, pediatric and adolescent users, gestational diabetes and patients at risk of hypoglycemia have stronger demand for real-time alerts, trend management and remote sharing. With reimbursement expansion and OTC product availability, CGM is extending into non-insulin type 2 diabetes, prediabetes, weight management, sports nutrition, corporate health management and clinical research data collection. In 2024, the FDA cleared the first OTC CGM, Dexcom Stelo, for adults aged 18 and older who do not use insulin, marking CGM’s expansion from prescription diabetes devices into broader metabolic health monitoring. Faster-growing directions are expected to include type 2 diabetes management, remote chronic disease management, smart insulin delivery systems, consumer metabolic health and AI-assisted glucose behavior analytics. From a production perspective, the United States, Europe, China and selected Asia-Pacific regions are the main R&D and manufacturing clusters for connected CGM systems. The United States hosts Dexcom, Medtronic, Senseonics and other representative companies, leading in high-end sensors, software algorithms, FDA regulatory pathways, reimbursement and closed-loop insulin delivery ecosystems. Europe has mature medical payment systems, clinical adoption and distribution networks, and is also an important expansion region for U.S. and Chinese vendors. China is building a relatively complete supply chain covering glucose enzymes, electrode materials, flexible sensors, patch packaging, Bluetooth communication, mobile applications, registration and local channels. China’s NMPA has approved MicroTech Medical’s innovative continuous glucose monitoring system registration application, and Sinocare has disclosed that its CGM system has obtained medical device registration certificates, reflecting faster commercialization of domestic CGM products in China. From a consumption perspective, North America remains the largest and most commercialized market globally, benefiting from a large diabetes population, commercial insurance and Medicare coverage, physician prescribing habits and a mature digital health ecosystem. Europe benefits from public healthcare systems and the promotion of CGM and hybrid closed-loop technologies by NICE and NHS. NHS England states that hybrid closed-loop systems link CGM with insulin pump technology and has set out a phased implementation strategy. China’s market opportunity comes from its large diabetes population, still-rising CGM penetration, price reduction by local brands, online chronic disease management and endocrinology education in hospitals. Japan, South Korea, Australia and selected high-income Middle Eastern markets have strong payment capability and digital healthcare foundations. Latin America, Southeast Asia and parts of the Middle East and Africa are at an early stage of upgrading from traditional blood glucose meters to CGM, where channel education, price segmentation and local compliance will determine market release speed. The upstream supply chain of connected CGM systems includes glucose oxidase or other biorecognition materials, precious metal and carbon-based electrode materials, flexible substrates, medical adhesives, insertion needles and implant components, micro-batteries, low-power Bluetooth chips, sensor ASICs, MCUs, memory chips, medical-grade plastic parts, sterile packaging and precision molds. Core equipment and enabling technologies include screen printing, thin-film deposition, electrochemical sensor fabrication, micro/nano processing, injection molding and packaging, automated assembly, sterilization, quality inspection and algorithm validation. The midstream includes sensor kits, transmitters or integrated patches, readers, mobile applications, cloud platforms, physician software and data analysis services. Downstream applications cover hospital endocrinology departments, diabetes clinics, retail pharmacies, DME channels, online chronic disease platforms, home care, commercial insurance health management, sports nutrition and clinical research. Key barriers are concentrated in sensor accuracy, batch consistency, anti-interference capability, wearing comfort, algorithm reliability, clinical validation, regulatory registration, payer access, data security and after-sales service. Higher-value links include high-consistency sensor manufacturing, algorithm platforms, brand channels, data ecosystems and recurring consumables. In the future, the supply chain will move toward localization, automated manufacturing, longer sensor life, software subscription, interoperability with insulin delivery systems and differentiated regional compliance systems. The policy and regulatory environment is pushing the industry to evolve from wearable monitoring devices into medical-grade digital chronic disease management systems. The U.S. FDA has developed clearer regulatory positions on integrated CGM, OTC CGM and unauthorized non-invasive products, encouraging compliant products to expand applications while warning that unauthorized smartwatches or smart rings cannot independently measure blood glucose and may create medication decision risks if data are inaccurate. The ADA 2026 Standards of Care emphasize CGM use at diabetes onset and thereafter for appropriate users to improve outcomes, which will further support clinical acceptance. Major industry barriers include sensor accuracy and stability, clinical evidence, data reliability across skin types and environments, reimbursement access, manufacturing yield, pricing pressure, data privacy, cybersecurity, cross-device interoperability certification and safety responsibility boundaries when linked with insulin pumps. Challenges mainly come from the strong channel advantages of leading brands, intensifying price competition, high education costs in consumer use cases, insufficient clinical evidence from some new entrants, and potential disruption from non-invasive alternatives over the long term. Over the next few years, connected CGM systems will continue to evolve toward smaller size, factory calibration, longer life, lower cost, stronger connectivity, better algorithms and broader usage scenarios. Core drivers include the expanding diabetes and metabolic disorder population, deeper clinical use of dynamic glucose metrics, broader payer coverage, telemedicine and home care development, maturation of AID and smart insulin pen ecosystems, and rising consumer demand for personalized nutrition and behavioral feedback. As localized supply chains and automated manufacturing improve, lower-price products will accelerate penetration in emerging markets, while premium markets will compete around long-term implantable CGM, closed-loop insulin delivery, AI prediction, clinical-grade data services and multi-parameter metabolic monitoring. Overall, connected CGM is evolving from a single glucose monitoring tool into a data entry point for digital chronic disease management and metabolic health, with sustained growth potential and expanding supply chain synergies. About QYResearch QYResearch founded in California, USA in 2007. It is a leading global market research and consulting company. With over 19 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future. QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US)   JP: https://www.qyresearch.co.jp